GlassScriptPhysician profile
Leslie Chana Neems
NPI 1396000758
$2,269.73
in general payments reported to CMS, 2019-2025
13 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $64.88 · 2022: $160 · 2023: $1,150 · 2024: $524 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $382.94 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $354.84 | 2023 | Tepezza |
| Abbvie INC. | $352.22 | 2023-2025 | |
| Glaukos Corporation | $182.22 | 2024 | Idose |
| Amgen INC. | $138.32 | 2024 | Tepezza |
| Stryker Corporation | $133.54 | 2021-2024 | Medpor Titan, Patient-Fitted Tmj Reconstructive Prosthesis System |
| Alcon Vision LLC | $120.88 | 2023 | Clareon |
| Endo Pharmaceuticals INC. | $120.10 | 2019 | |
| Integra Lifesciences Corporation | $118.08 | 2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Merz North America, INC. | $100.42 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $97.81 | 2023 | Libtayo |
| Depuy Synthes Sales INC. | $84.87 | 2023 | Matrixcombo |
| Novo Nordisk INC | $83.49 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Neems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.